Tesamorelin (Egrifta): What the Research Shows

Educational Notice

This article is written for researchers, clinicians, and informed adults seeking to understand the scientific literature on tesamorelin. It is not medical advice, a treatment recommendation, or an endorsement of any specific use. Tesamorelin (Egrifta) is FDA-approved for a specific indication: reduction of excess abdominal fat in HIV-infected patients with antiretroviral-associated lipodystrophy. Use outside this approved indication is off-label. Tesamorelin is prohibited in competitive sport under WADA regulations. Consult a qualified healthcare professional before making any health or treatment decisions.

Tesamorelin is the only FDA-approved compound in the Growth Hormone Secretagogues cluster. Theratechnologies Inc. received FDA approval in 2010 for Egrifta—tesamorelin acetate for injection—for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a body fat redistribution syndrome caused by long-term antiretroviral therapy. The approval was based on two Phase III randomized controlled trials demonstrating statistically significant visceral adipose tissue reduction and was supported by an FDA Advisory Committee recommendation. This is the gold standard of evidence in this cluster.

That FDA approval creates an unusual situation. Tesamorelin has the most rigorous clinical evidence of any compound covered in the Growth Hormone Secretagogues cluster—genuine Phase III RCT data in a defined patient population. At the same time, the approved indication is narrow and specific: HIV-associated lipodystrophy. The compound is increasingly used off-label for general body composition purposes, for visceral fat reduction in non-HIV adults, and for potential cognitive benefits in aging populations. The off-label uses have Phase II evidence support but not the Phase III evidence base of the approved indication.

Understanding tesamorelin requires keeping the approved indication and the off-label uses clearly distinguished. The evidence for VAT reduction in HIV lipodystrophy is as strong as any evidence for any peptide on this site. The evidence for body composition enhancement in healthy non-HIV adults is Phase II level. These are different evidence questions with different answers.

Approved Drug Tier

Tesamorelin is assigned the Approved Drug evidence tier on Peptidings—reserved for compounds with FDA approval for at least one indication. This tier reflects the quality of evidence for the approved indication. It does not imply that all uses of tesamorelin are equivalent to the approved use.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Quick Facts

Type Synthetic GHRH analog with trans-3-hexenoic acid N-terminal modification
Brand name Egrifta (Theratechnologies)
Molecular weight ~5135 Da
Target receptor GHRHR (growth hormone-releasing hormone receptor)
Mechanism GHRHR agonist → pulsatile pituitary GH release; N-terminal modification protects against DPP-IV cleavage
Plasma half-life ~26–38 minutes (subcutaneous)
GH profile Pulsatile — discrete GH pulses, physiologically patterned
Route of administration Subcutaneous injection (once daily)
Developer Theratechnologies Inc. (Canada)
FDA status Approved — Egrifta; indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
WADA status Prohibited—S2 (Peptide Hormones, Growth Factors, and Related Substances)
Evidence tier Approved Drug — for HIV-associated lipodystrophy; highest evidence tier in the cluster
Key distinction The only FDA-approved compound in the Growth Hormone Secretagogues cluster; approved for a specific, narrow indication; off-label body composition use is a different evidence question

What Is Tesamorelin?

Tesamorelin is a 44-amino acid GHRH analog modified with a trans-3-hexenoic acid group at the N-terminus. GHRH itself is a 44-amino acid hypothalamic peptide; tesamorelin retains the full sequence but the N-terminal modification protects the critical residues from cleavage by dipeptidyl peptidase IV (DPP-IV), the plasma enzyme that rapidly inactivates endogenous GHRH. This modification extends the compound’s half-life to approximately 26–38 minutes following subcutaneous injection—longer than endogenous GHRH (less than 10 minutes) but shorter than CJC-1295 formulations.

Tesamorelin acts at the GHRHR on pituitary somatotrophs, activating Gs/cAMP/PKA signaling to drive GH exocytosis. The GH pulses produced are pulsatile and physiologically patterned—once-daily injection produces a GH pulse that peaks and then returns to baseline, preserving the pulsatile architecture of GH secretion that the body normally employs. Somatostatin feedback and IGF-1 negative feedback remain operative, constraining GH excess in the same way as with sermorelin and CJC-1295 without DAC.

The key clinical application—VAT reduction in HIV lipodystrophy—reflects GH’s known lipolytic effects on visceral adipose tissue. HIV-associated lipodystrophy involves abnormal visceral fat accumulation that is partly attributable to GH axis dysregulation induced by antiretroviral therapy. Tesamorelin corrects this dysregulation by stimulating GH release, which in turn reduces visceral fat through lipolytic mechanisms.

Origins and FDA Approval History

Theratechnologies, a Canadian biopharmaceutical company, developed tesamorelin with the specific goal of treating HIV-associated lipodystrophy—a condition with no approved pharmacological therapy at the time and significant unmet medical need. Antiretroviral therapy had transformed HIV into a manageable chronic condition, but the metabolic side effects of long-term ART—particularly visceral fat accumulation and associated cardiovascular risk—were significant quality-of-life and health issues for the growing population of HIV+ adults on long-term therapy.

The Phase III clinical program consisted of two pivotal RCTs (Falutz et al. 2007, 2010) that enrolled a combined 818 HIV+ adults with lipodystrophy. Both trials demonstrated statistically significant VAT reduction versus placebo at 26 weeks, with effects maintained in the 52-week extension. The FDA approved Egrifta on November 10, 2010, making it the first pharmacological treatment for HIV-associated lipodystrophy.

Following approval, the compound has been studied in additional contexts—non-HIV obese adults, older adults with age-related visceral fat accumulation, and populations with mild cognitive impairment. This secondary research program represents a meaningful and growing evidence base beyond the approved indication, though it has not yet generated Phase III data in any of these additional populations.

Mechanism of Action

Tesamorelin acts at the GHRHR on pituitary somatotrophs. Receptor activation stimulates Gs protein, adenylyl cyclase, and cAMP accumulation, activating PKA and driving GH release from secretory granules. The mechanism is identical to endogenous GHRH’s action; tesamorelin differs only in its DPP-IV resistance that extends its active life in circulation.

Plain English

Tesamorelin mimics your body’s natural growth-hormone-release signal. It binds to the same pituitary receptor and triggers a pulse of growth hormone—just like the brain’s own signaling molecule, but engineered to last longer by resisting the enzyme that normally breaks it down within minutes.

The lipolytic mechanism relevant to the approved indication: elevated GH stimulates lipolysis in adipose tissue via hormone-sensitive lipase activation, promoting mobilization of stored triglycerides. Visceral adipose tissue is particularly GH-responsive—it has high density of GH receptors and responds more robustly to GH-driven lipolysis than subcutaneous fat. This receptor distribution partly explains why tesamorelin produces disproportionate VAT reduction relative to subcutaneous fat loss.

Plain English

The growth hormone tesamorelin releases tells fat cells to break down stored fat. Deep belly fat has more GH receptors than the fat under your skin, so it responds more strongly—which is why tesamorelin specifically shrinks abdominal fat rather than fat everywhere equally.

As with all GHRHR agonists, feedback mechanisms remain intact: rising IGF-1 and GH trigger hypothalamic somatostatin release, limiting GH excess. The once-daily subcutaneous injection produces a GH pulse that rises and returns to baseline before the next dose, maintaining pulsatile GH secretion architecture.

Plain English

Your body’s built-in safety brake still works with tesamorelin. When growth hormone rises too high, the brain releases a stop signal (somatostatin) that brings it back down—unlike injecting GH directly, which bypasses this natural control entirely.

The Approved Indication: HIV-Associated Lipodystrophy

HIV-associated lipodystrophy is a metabolic syndrome affecting HIV+ adults on long-term antiretroviral therapy, characterized by visceral fat accumulation (trunk and abdominal), peripheral fat loss (face, limbs), dyslipidemia, and insulin resistance. The visceral fat component—which Egrifta specifically addresses—is associated with increased cardiovascular risk, metabolic syndrome, and significant cosmetic distress affecting quality of life and medication adherence.

The Phase III trials enrolled adults meeting defined lipodystrophy criteria (VAT ≥130 cm² on abdominal CT) who had been on stable antiretroviral therapy. Primary endpoint in both trials was change in VAT at 26 weeks by CT measurement. Both trials met their primary endpoints with clinically meaningful VAT reduction (~15% relative reduction versus increase in placebo groups).

Importantly, the VAT reduction attenuates after discontinuation—visceral fat returns toward baseline when tesamorelin is stopped. This means ongoing treatment is required to maintain the effect, which has implications for long-term use, adverse effect accumulation, and cost. The FDA-approved prescribing information addresses this as an expected characteristic of the treatment.

The Indication Boundary

FDA approval for HIV-associated lipodystrophy does not mean tesamorelin is an approved body composition drug for the general population. The approved indication reflects a specific disease state with defined pathophysiology and documented unmet medical need. Using tesamorelin for general body composition in non-HIV adults is off-label use—supported by Phase II data but not by the Phase III evidence that earned the approved indication.

Key Research Areas and Studies

HIV-Associated Lipodystrophy (Approved Indication)

The two pivotal Phase III trials represent the strongest evidence base for any compound in this cluster. Both were randomized, double-blind, placebo-controlled, multi-center trials with objective CT measurement of VAT as the primary endpoint. The consistent significant findings across both trials—approximately 15% relative VAT reduction versus ~5% increase in placebo over 26 weeks—provide the highest level of evidence for any application of tesamorelin.

Non-HIV Visceral Fat and Body Composition

Dhillon et al. (2018) conducted Phase II research in non-HIV overweight adults, showing tesamorelin produced significant VAT reduction versus placebo. This extends the VAT-reduction evidence beyond the approved indication and supports the pharmacological plausibility of off-label use, though it is Phase II data.

Cognitive Function

Baker et al. (2012) conducted a substudy examining cognitive outcomes in HIV+ older adults receiving tesamorelin. Improvements in executive function and verbal memory were observed versus placebo. This finding has generated ongoing research interest in tesamorelin for age-related cognitive decline. Results from subsequent trials in non-HIV populations with mild cognitive impairment are preliminary but represent one of the more mechanistically coherent cognitive-enhancement applications among research peptides.

Common Claims versus Current Evidence

Claim Evidence Verdict
Tesamorelin reduces abdominal fat in HIV patients with lipodystrophy FDA-approved based on two Phase III RCTs demonstrating statistically significant visceral adipose tissue (VAT) reduction in HIV patients on antiretroviral therapy. This is the highest-quality evidence of any effect for any compound in this cluster. Approved — Phase III Evidence
Tesamorelin reduces abdominal fat in non-HIV adults Phase II data exists showing VAT reduction in non-HIV overweight adults. Dhillon et al. (2018) showed significant VAT reduction vs placebo. The magnitude and durability of effect in non-HIV populations, and the benefit-risk profile outside the approved indication, is less established than in the HIV population. Phase II Supported
Tesamorelin improves cognitive function Preliminary Phase II data (Baker et al. 2012 and follow-up work) suggests tesamorelin may improve executive function in HIV+ and non-HIV older adults. This is an actively researched area; findings are preliminary but more substantial than for most research peptides in the cluster. Phase II — Promising
Tesamorelin improves cardiovascular risk markers VAT reduction is associated with improvements in triglycerides and other metabolic markers in the Phase III trials. The cardiovascular risk reduction is inferred from the metabolic marker improvements; direct cardiovascular outcomes data does not exist. Inferred from VAT Reduction
Tesamorelin is equivalent to GH replacement for body recomposition Tesamorelin acts through pituitary-regulated GH secretion, not direct GH delivery. Effects are constrained by pituitary feedback mechanisms. The body composition effects, while documented in specific populations, are not equivalent to supraphysiological GH replacement and should not be characterized as such. Misleading
Tesamorelin can be used off-label for body composition in healthy adults Tesamorelin is FDA-approved for one specific population and indication. Off-label use is legal but the evidence base for body composition benefit in healthy non-HIV adults without lipodystrophy is Phase II only. The approved indication reflects a defined clinical need; using it off-label for general body composition enhancement is a different evidence question. Phase II Only—Off-Label Context

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

The Human Evidence Landscape

Tesamorelin has the most rigorous evidence base in the Growth Hormone Secretagogues cluster by virtue of its FDA-approved Phase III program. For its approved indication—VAT reduction in HIV lipodystrophy—the evidence quality is not comparable to the other compounds in this cluster; it is simply better: two Phase III RCTs, objective endpoint measurement, controlled design, and regulatory review.

The off-label landscape is more nuanced. Phase II data in non-HIV populations shows VAT reduction signals. Cognitive benefit data is preliminary but mechanistically coherent. The absence of Phase III data in any off-label population means the benefit-risk calculation for off-label use is less certain than for the approved indication.

The cognitive research is worth watching. If tesamorelin’s Phase II cognitive findings replicate in larger trials in age-related cognitive decline or MCI populations, it could represent a uniquely evidence-supported application of a GHRH analog. This is in active investigation as of this writing.

Safety, Risks, and Limitations

Established Safety Profile from Phase III

The pivotal trials provide the most comprehensive safety data of any compound in the cluster. Common adverse effects: injection site reactions (most common), fluid retention and edema, arthralgia (joint pain), and peripheral sensory neuropathy (less common). The compound was generally well-tolerated in the HIV+ populations studied.

Glucose and Insulin

GH elevation impairs insulin sensitivity—a class effect. In the Phase III trials, fasting glucose and insulin measures showed modest worsening in the tesamorelin group versus placebo. For HIV+ patients already at elevated metabolic risk from antiretroviral therapy, this is a clinically relevant consideration. Glucose monitoring is part of the approved prescribing protocol.

VAT Returns After Discontinuation

When tesamorelin is stopped, visceral fat returns toward pre-treatment levels. This is documented in the Phase III extension data. For the approved indication, this means treatment must be continued to maintain the effect—ongoing injection burden and cost. For off-label users, this means effects are not permanent and cessation reverses benefits.

IGF-1 Elevation and Long-Term Surveillance

Post-marketing surveillance for Egrifta includes monitoring for IGF-1 elevation above normal range. Sustained supraphysiological IGF-1 is theoretically associated with increased cancer risk; this is monitored as part of the approved prescribing protocol. For off-label use without prescriber oversight, IGF-1 monitoring is the user’s responsibility.

FDA Status

Tesamorelin (Egrifta) is FDA-approved for reduction of excess abdominal fat in HIV-infected patients with antiretroviral-associated lipodystrophy. This is a prescription drug. Off-label prescribing is legal; obtaining tesamorelin outside of a prescription context is not FDA-approved use. Research-grade tesamorelin from non-pharmaceutical suppliers is not the FDA-approved Egrifta and is not subject to the quality standards of the approved formulation.

WADA Status

WADA Prohibition

Tesamorelin is prohibited under WADA S2 both in-competition and out-of-competition, despite its FDA-approved status for a medical indication. FDA approval for a medical use does not grant exemption from WADA prohibition. Athletes with a documented medical need (HIV lipodystrophy) may apply for a Therapeutic Use Exemption through their national anti-doping organization.

Research Protocols and Laboratory Practices

Egrifta is supplied as lyophilized powder with a separate diluent vial, reconstituted immediately before each injection. The approved prescribing information specifies reconstitution procedure and injection technique. Research-grade tesamorelin follows standard lyophilized peptide reconstitution with bacteriostatic water: store at 2–8°C (35–46°F), reconstitute immediately before use or within 28 days with bacteriostatic water, do not freeze reconstituted solution.

Reconstitution vs. Dosing Syringes

Standard subcutaneous injection technique. Abdomen preferred injection site per prescribing information—rotate within the same general area. 2 mg is the approved once-daily dose; inject at approximately the same time each day to maintain consistent GH stimulation timing.

Dosing in Published Research

Study / Source Population Dose Route Duration Key Findings
Falutz J, et al. NEJM 2007 (Pivotal Trial 1) HIV+ adults with lipodystrophy (n=412) 2 mg/day SC 26 weeks, then 52-week extension Significant VAT reduction vs placebo (−15% vs +5%); maintained at 52 weeks; improved triglycerides; well-tolerated
Falutz J, et al. JAIDS 2010 (Pivotal Trial 2) HIV+ adults with lipodystrophy (n=406) 2 mg/day SC 26 weeks Replicated Phase III results; confirmed VAT reduction; basis for FDA approval of Egrifta
Dhillon S, et al. Drugs 2018 Non-HIV overweight adults (Phase II) 1–2 mg/day SC 6 months Significant VAT reduction in non-HIV population; promising non-approved-indication data
Baker LD, et al. Arch Neurol 2012 HIV+ older adults, MCI substudy 2 mg/day SC 20 weeks Improved executive function and verbal memory; preliminary cognitive benefit signal
Stanley TL, et al. AIDS 2019 HIV+ adults on ART 2 mg/day SC 52 weeks VAT reduction maintained; IGF-1 normalization; modest lean mass improvement

Uniquely Established Dose

Tesamorelin is unusual in the cluster for having a clinically validated, regulatory-reviewed dose of 2 mg SC daily. This is the dose used in both Phase III trials and approved in the prescribing information. Community protocols that follow this dose are using the same dose that generated the approval evidence.

Dosing in Independent Self-Experimentation Communities

Protocol Parameter Typical Community Range Notes
Dose 1–2 mg/day; 2 mg matches the approved clinical dose The FDA-approved dose is 2 mg SC daily. Community protocols generally follow this, making tesamorelin unusual among research peptides in having an established clinically validated dose.
Frequency Once daily SC injection Unlike shorter-acting GHRH analogs, once-daily dosing of tesamorelin produces adequate pulsatile GH stimulation for its approved indication.
Target population (approved) HIV+ adults with antiretroviral-associated lipodystrophy The approved indication is narrow and specific. Community use for general body composition occurs in a different population.
Off-label use context General body composition, VAT reduction in non-HIV adults, cognitive enhancement Phase II evidence supports some efficacy signals in non-HIV populations. Long-term safety and benefit-risk in healthy adults is not as well characterized as in the approved indication.
Effect on visceral fat Documented VAT reduction in approved population; Phase II evidence in non-HIV VAT (visceral adipose tissue) reduction is specifically documented—this is not general fat loss. Subcutaneous fat responds less consistently.
Monitoring IGF-1 levels, fasting glucose Standard secretagogue monitoring. Tesamorelin also raises insulin resistance concerns (GH class effect) though less prominently documented than with MK-677.

Frequently Asked Questions

Is tesamorelin the same as regular GHRH?

No. Tesamorelin is a modified GHRH analog with a trans-3-hexenoic acid group attached to the N-terminus that protects against DPP-IV cleavage. Endogenous GHRH has a half-life of less than 10 minutes; tesamorelin’s half-life is 26–38 minutes. Both act at the same receptor (GHRHR) with the same mechanism, but tesamorelin has clinically meaningful duration of action that natural GHRH lacks.

Can tesamorelin be used without an HIV diagnosis?

Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy. Off-label prescribing by physicians for other indications is legal. Using research-grade tesamorelin purchased outside of a prescription context is not FDA-approved use. Phase II evidence supports VAT reduction in non-HIV adults, but this has not been reviewed or endorsed by the FDA for non-HIV populations.

How does tesamorelin compare to other GHRH analogs?

Tesamorelin retains the full 44-amino acid GHRH sequence (versus sermorelin’s 29-amino acid truncation), which may contribute to different potency and specificity characteristics. Its half-life (~26–38 min) is longer than sermorelin (~10–20 min) but shorter than CJC-1295 without DAC modified forms. The most important distinguishing feature is the Phase III evidence base and FDA approval—no other GHRH analog in community use carries this.

Does tesamorelin work for general fat loss?

Tesamorelin specifically reduces visceral adipose tissue (VAT)—the fat depot surrounding the abdominal organs. It has much less consistent effect on subcutaneous fat. For people specifically concerned about visceral fat (cardiometabolic risk, abdominal circumference), the evidence is more supportive than for general fat loss. Using tesamorelin primarily for subcutaneous fat or overall scale weight reduction is not well-supported by the evidence.

Related Peptides: How Tesamorelin Compares

Compound Receptor Route GH Profile Appetite Half-life Evidence Tier FDA Status
Ipamorelin GHS-R1a Peptide SC Moderate pulse Minimal ~2 hr Preclinical / Phase I Cat. 3
CJC-1295 no DAC GHRHR Peptide SC Moderate pulse None ~30 min Preclinical / Phase I Cat. 3
CJC-1295 with DAC GHRHR (albumin-bound) Peptide SC Strong, sustained ~14 days None ~14 days Phase I/II Cat. 3
Sermorelin GHRHR Peptide SC Moderate pulse None ~10–20 min Clinical / Prior FDA approval Cat. 3
MK-677 GHS-R1a Non-peptide oral Strong, sustained ~24 hr Moderate ~24 hr Phase II/III Cat. 3
Tesamorelin GHRHR Peptide SC Moderate pulse None ~26–38 min Approved Drug (HIV lipodystrophy) FDA approved — Egrifta
Edit
Compound Type Primary Target Half-Life FDA Status WADA Status Evidence Tier Weight Loss Efficacy Route Mechanism Class Key Differentiator
Semaglutide Synthetic GLP-1 receptor agonist peptide GLP-1R ~7 days FDA-approved (Wegovy, Ozempic) Prohibited — S4 (Class 2 Hormone/Analogs) Tier 1 — Approved Drug Up to 22% body weight reduction (Phase III) Subcutaneous injection (weekly) GLP-1 agonist Longest half-life in class; once-weekly dosing. Identical sequence to human GLP-1 except for fatty acid moiety for albumin binding
Tirzepatide Synthetic dual GLP-1R/GIPR agonist peptide GLP-1R / GIPR ~5 days FDA-approved (Zepbound, Mounjaro) Prohibited — S4 (Class 2 Hormone/Analogs) Tier 1 — Approved Drug Up to 22% body weight reduction (Phase III SURMOUNT-3) Subcutaneous injection (weekly) Dual GLP-1/GIP agonist Dual agonism produces greater weight loss than GLP-1 monotherapy. Glucose-dependent mechanism
Retatrutide Synthetic triple GLP-1R/GIPR/GcgR agonist peptide GLP-1R / GIPR / GcgR ~5 days Phase III clinical trials (not yet approved) Prohibited — S4 (Class 2 Hormone/Analogs) — projected Tier 2 — Clinical Trials (Phase III) Up to 24% body weight reduction (Phase II) Subcutaneous injection (weekly) Triple GLP-1/GIP/glucagon agonist Broadest receptor coverage in development. Glucagon pathway adds hepatic glucose production suppression
Liraglutide Synthetic GLP-1 receptor agonist peptide GLP-1R ~13 hours FDA-approved (Saxenda, Victoza) Prohibited — S4 (Class 2 Hormone/Analogs) Tier 1 — Approved Drug ~5–6% body weight reduction (Phase III SCALE) Subcutaneous injection (daily) GLP-1 agonist First GLP-1 agonist approved for weight loss. Daily dosing; shorter half-life than semaglutide
Orforglipron Synthetic selective GLP-1 receptor agonist peptide GLP-1R ~11 hours Phase II clinical trials (pending) Prohibited — S4 (Class 2 Hormone/Analogs) — projected Tier 2 — Clinical Trials (Phase II) Up to 15% body weight reduction (Phase II interim) Oral (non-peptide-like oral bioavailability) GLP-1 agonist (oral) Oral formulation in development. If approved, would offer first oral GLP-1 class agent for weight loss
CagriSema Synthetic fixed-ratio triple agonist (GLP-1/GIP/GcgR + amylin) GLP-1R / GIPR / AmylinR / GcgR ~5 days (tirzepatide component) Phase II clinical trials (pending) Prohibited — S4 (Class 2 Hormone/Analogs) — projected Tier 2 — Clinical Trials (Phase II) Up to 20% body weight reduction (Phase II interim) Subcutaneous injection (weekly) Quadruple agonist (GLP-1/GIP/amylin/glucagon) Broadest receptor profile in development. Amylin pathway targets satiety and gastric emptying synergistically
Survodutide Synthetic dual GLP-1R/GcgR agonist peptide GLP-1R / GcgR ~3–4 days Phase II clinical trials (pending) Prohibited — S4 (Class 2 Hormone/Analogs) — projected Tier 2 — Clinical Trials (Phase II) Up to 18% body weight reduction (Phase II interim) Subcutaneous injection (weekly) GLP-1/glucagon dual agonist Glucagon pathway without GIP agonism. May offer weight loss with reduced nausea vs. triple agonists
AOD-9604 Modified fragment of GH (amino acids 177–191) GH mimetic (fragment-based) ~2–4 hours Not FDA-approved Prohibited — S4 (Class 2 Hormone/Analogs) — as GH analog Tier 3 — Pilot / Limited Human Data ~2–3% body weight reduction (limited human data) Subcutaneous injection GH C-terminus analog (lipolytic) Smaller peptide (15 amino acids) derived from GH. Lipolytic effect without GH-typical muscle anabolism claims
5-Amino-1MQ Synthetic small molecule quinone metabolite analog NNMT inhibitor ~6–8 hours Not FDA-approved Not WADA-listed — emerging research compound Tier 4 — Preclinical Only ~5–8% body weight reduction (mouse models only; limited human data) Oral (small molecule) NNMT inhibition (NAD+ pathway) Non-peptide. Targets mitochondrial NAD+ metabolism. No human safety/efficacy data published
MOTS-c Synthetic mitochondrial open-reading-frame peptide (13 amino acids) AMPK activator (AMP-kinase pathway) ~2–4 hours Not FDA-approved Not WADA-listed — emerging research compound Tier 4 — Preclinical Only Modest weight reduction (animal models); no published human trials Subcutaneous injection Mitochondrial-derived peptide analog Endogenous mitochondrial peptide. Activates AMPK/SIRT pathway. Only mouse models published
Tesamorelin Synthetic GHRH analog (1-44 amino acids, GHRH-analogue with acyl modification) GHRH-R ~26 minutes FDA-approved (Egrifta for lipodystrophy in HIV) Prohibited — S2 (GHRH analog) Tier 1 — Approved Drug ~2–4% visceral fat reduction (HIV lipodystrophy indication) Subcutaneous injection (daily) GHRH analog Only GH secretagogue approved by FDA for visceral adiposity. Raises GH indirectly via pituitary. Limited weight loss data in non-HIV populations

Summary and Key Takeaways

Tesamorelin is the only FDA-approved compound in the Growth Hormone Secretagogues cluster, and the evidence quality for its approved indication—VAT reduction in HIV-associated lipodystrophy—is the highest of any application for any compound on this site. The Phase III evidence is real, rigorous, and provides a clear clinical picture. The off-label applications (general body composition, cognitive enhancement, non-HIV visceral fat reduction) have Phase II support but require the distinction between approved and off-label use to be kept clear.

  • Tesamorelin is a full-length GHRH analog producing pulsatile GH stimulation via GHRHR activation.
  • FDA-approved as Egrifta for HIV-associated lipodystrophy—the only approved compound in this cluster.
  • Two Phase III RCTs demonstrate significant VAT reduction in HIV+ adults with lipodystrophy; this is the strongest evidence for any single effect of any compound in the GH Secretagogues cluster.
  • Phase II data supports VAT reduction in non-HIV adults. Cognitive benefit signals are preliminary but mechanistically coherent and actively studied.
  • VAT returns toward baseline after discontinuation; ongoing treatment is required to maintain effects.
  • WADA-prohibited under S2 both in- and out-of-competition, despite FDA-approved medical status. Athletes with a legitimate medical indication may apply for a Therapeutic Use Exemption.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References and Key Studies

  1. Falutz J, et al. Metabolic effects of a growth hormone–releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–70. — Pivotal Phase III trial 1.
  2. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Acquir Immune Defic Syndr. 2010;53(3):311–22. — Pivotal Phase III trial 2 and pooled analysis.
  3. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071–91.
  4. Baker LD, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420–9.
  5. Stanley TL, et al. Effects of switching from stavudine or zidovudine to tenofovir disoproxil fumarate on body composition and abdominal fat among HIV-infected adults with lipodystrophy. AIDS. 2019 (reference for long-term extension data).
  6. Egrifta (tesamorelin) prescribing information. Theratechnologies Inc. FDA NDA 022505.

Further Reading and References

  • Sermorelin article at peptidings.com/peptides/sermorelin/ — other GHRH analog comparison
  • CJC-1295 (no DAC) article at peptidings.com/peptides/cjc-1295/ — shorter-acting GHRH analog
  • Growth Hormone Secretagogues Cluster Hub at peptidings.com/peptides/growth-hormone-secretagogues/
  • Peptidings Evidence Levels explainer at peptidings.com/peptide-evidence-levels/
  • FDA Egrifta product page: accessdata.fda.gov (NDA 022505)

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing in this article should be interpreted as an endorsement of any compound for human use outside of properly conducted clinical trials.

Tesamorelin (Egrifta) information is provided for research and educational purposes only. Readers are responsible for understanding and complying with all applicable laws in their jurisdiction.

All citations link to primary sources where available. Where cited studies are limited to animal models or early-phase trials, that limitation is stated explicitly in the text and is not minimized.

Scroll to Top